So far Friday, July 5, NASDAQ is up 0.96% and the S&P is up 0.32%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBB – Research Report), OHR Pharmaceutical (OHRP – Research Report), Karyopharm Therapeutics (KPTI – Research Report), Dynavax (DVAX – Research Report) and OncoSec Medical (ONCS – Research Report).

American Green Inc is down -33.33% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

OHR Pharmaceutical is up 15.82% in midday trading to $3.66. Shares opened today at $3.16. The company has a 52-week low of $1.58 and a 52-week high of $0.00.

Karyopharm Therapeutics is down -12.13% in midday trading to $8.91. Shares opened today at $10.14. The company has a 52-week low of $3.92 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $21.50, marking a 112.03% potential upside from current levels. In a report released today, Wedbush analyst David Nierengarten maintained a Buy rating on KPTI, with a price target of $11, which represents a potential upside of 8% from where the stock is currently trading.

See today’s analyst top recommended stocks >>

Dynavax is down -9.78% in midday trading to $4.11. Shares opened today at $4.55. The company has a 52-week low of $3.57 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $23.67, marking a 420.22% potential upside from current levels. In a report issued on June 17, William Blair analyst Matt Phipps reiterated a Buy rating on DVAX.

OncoSec Medical is up 8.85% in midday trading to $2.46. Shares opened today at $2.26. The company has a 52-week low of $2.17 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $10.00, marking a 342.48% potential upside from current levels. In a report issued on June 28, Maxim Group analyst Jason McCarthy maintained a Buy rating on ONCS, with a price target of $10, which implies an upside of 342% from current levels. Over the last 3 months, the insider sentiment on OncoSec Medical has been positive based on 15 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>